

Investor News

NeuroSearch to present at the JP Morgan Healthcare conference, January 2008 in San Francisco

NeuroSearch has been invited to present at the next annual JP Morgan Healthcare conference to be held on 7 – 10 January 2008 in San Francisco, US. It will be the 26th time, the JP Morgan Healthcare conference is being held as the largest and most well-attended investor conference in the healthcare industry.

Flemming Pedersen, CEO of NeuroSearch, commented:

"It is of major importance to us that we have been invited to present at the JP Morgan conference as one out of relatively few European biopharmaceutical companies. It proves that NeuroSearch has now grown to reach a position among the largest and internationally most renowned companies in this industry."

NeuroSearch's presentation is scheduled for

Monday 7 January 2008 at 2:30 pm (EST).

to be held by CEO Flemming Pedersen.

In his presentation, Flemming Pedersen will give an update on NeuroSearch's comprehensive pipeline, currently counting 17 drug candidates in development. The focus of the presentation will be on the prospects for the company's two Phase III programmes; ACR16 for the treatment of Huntington's disease and tesofensine for the treatment of obesity.

A PowerPoint version of the presentation will be accessible on the company's website www.neurosearch.com prior to the presentation at the conference.

Contact person:

Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate Communications, telephone: +45 4017 5103

NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on the OMX Nordic Exchange Copenhagen A/S. The core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and CNS disorders. A substantial part of NeuroSearch's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. The drug pipeline comprises 11 clinical (Phase I-III) development programmes: ACR16 in Huntington's disease (Phase III in preparation), tesofensine in obesity (Phase III in preparation), NS2359 in depression (Phase II) and ADHD (Phase II) in partnership with GSK, NS1209 in epilepsy and pain (Phase II), ABT-894 in ADHD (Phase II) and pain (Phase II) in partnership with Abbott, ACR16 in schizophrenia (Phase I) in partnership with Astellas, ACR325 in bipolar disorder and Parkinson's disease (Phase I) and ABT-107 as well as ABT-560 for the treatment of various CNS diseases – both (Phase I) in collaboration with Abbott as well as NSD-644 (Phase I) in collaboration with GSK. In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and holds equity interests in several biotech companies.